A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions

Colon CancerResected Stage

Interventions

DRUG

Cetuximab

Given IV

DRUG

Expanded CB-NK cells

Given IV

DRUG

Fludarabine phosphate

Given IV

DRUG

Cyclophosphamide

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER